Pros and cons of new oral anticoagulants in the treatment of venous thromboembolism in patients with cancer

Internal and Emergency Medicine

Volumn 10, Issue 6, 2015, Pages 651-656

  Verso, Melina ^a   Agnelli, Giancarlo ^a   Prandoni, Paolo ^b  

^a UNIVERSITY OF PERUGIA   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

Cancer patients; New oral anticoagulants; Treatment; Venous thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; DABIGATRAN; EDOXABAN; LOW MOLECULAR WEIGHT HEPARIN; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; PYRIDONE DERIVATIVE; RIVAROXABAN; THIAZOLE DERIVATIVE;

COMPLICATION; HUMAN; NEOPLASMS; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; DABIGATRAN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; NEOPLASMS; PYRAZOLES; PYRIDINES; PYRIDONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RIVAROXABAN; THIAZOLES; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

EID: 84940719205     PISSN: 18280447     EISSN: 19709366     Source Type: Journal    
DOI: 10.1007/s11739-015-1233-5     Document Type: Review

References (35)

1. Agnelli G, Verso M, Mandalà M, Gallus Cimminiello C et al (2014) A prospective study on survival in cancer patients with and without venous thromboembolism. Intern Emerg Med 9:559–567
2. Lyman Gary H (2014) Impact of venous thromboembolism on survival in patients with advanced cancer: an unmet clinical need. Intern Emerg Med 9:497–499
3. Blom JW, Doggen CJ, Osanto S, Rosendaal FR (2005) Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 293:715–722
4. Prandoni P, Lensing AW, Piccioli A, Bernardi E, Simioni P et al (2002) Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 100:3484–3488
5. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O’Fallon WM et al (2000) Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 160:809–815
6. Hutten BA, Prins MH, Gent M, Ginsberg J, Tijssen JG et al (2000) Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol 18:3078–3083
7. Heit JA, Mohr DN, Silverstein MD, Petterson TM, O’Fallon WM et al (2000) Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population- based cohort study. Arch Intern Med 160:761–768
8. Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK et al (2003) Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349:146–153
9. Meyer G, Marjanovic Z, Valcke J, Lorcerie B, Gruel Y et al (2002) Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 162:1729–1735
10. Hull RD, Pineo GF, Brant RF, Mah AF, Burke N et al (2006) Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med 119:1062–1072
11. Deitcher SR, Kessler CM, Merli G, Rigas JR, Lyons RM et al (2006) Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clin Appl Thromb Hemost 12:389–396
12. Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H et al (2012) Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141:e419S–e494S
13. Chong LY, Fenu E, Stansby G, Hodgkinson S, Guideline Development G (2012) Management of venous thromboembolic diseases and the role of thrombophilia testing: summary of NICE guidance. BMJ 344:e3979
14. Baglin TP, Keeling DM, Watson HG, British Committee for Standards in H (2006) Guidelines on oral anticoagulation (warfarin): third edition—2005 update. Br J Haematol 132:277–285
15. Lyman GH, Bohlke K, Khorana AA, Kuderer NM, Lee AY et al (2015) Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update 2014. J Clin Oncol 33:654–656
16. Barni M, Falanga A, Mandalà M et al (2013) Venous thromboembolism and cancer: guidelines of the Italian Association of Medical Oncology (AIOM) http://www.aiom.it/C_Common/Download.asp?file=/$Site$/Attivita_Scientifica/Linee_Guida/2013/Tromboembolismo_W9_27.09.2013.pdf
17. Prandoni Paolo (2010) The treatment of venous thromboembolism in patients with cancer. Intern Emerg Med 5:27–30
18. EINSTEIN investigators, Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H et al (2010) Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 363:2499–2510
19. Buller HR, Prins MH, Lensing AW, Decousus H, Jacobson BF et al (2012) Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 366:1287–1297
20. Buller HR, Decousus H, Grosso MA, Mercuri M, Middeldorp S et al (2013) Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 369:1406–1415
21. Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S et al (2009) Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 361:2342–2352
22. Schulman S, Kakkar AK, Goldhaber SZ, Schellong S, Eriksson H et al (2014) Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation 129:764–772
23. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS et al (2013) Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 369:799–808
24. Loffredo L, Perri L, Del Ben M, Angelico F, Violi F (2014) New oral anticoagulants for the treatment of acute venous thromboembolism: are they safer than vitamin K antagonists? A meta-analysis of the interventional trials. Intern Emerg Med. doi:10.1007/s11739-014-1171-7
25. Akl EA, Labedi N, Barba M, Terrenato I, Sperati F et al (2011) Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev (6):CD006650. doi:10.1002/14651858.CD006650.pub3
26. Vedovati MC, Germini F, Agnelli G, Becattini C (2015) Direct oral anticoagulants in patients with venous thromboembolism and cancer: a systematic review and meta-analysis. Chest 147:475–483
27. Van der Hulle T, den Exter PL, Kooiman J, van der Hoeven JJM, Huisman MV et al (2014) Meta-analysis of the efficacy and safety of new oral anticagulants in patients with cancer and venous thromboembolism. J Thormb Haemost 12:1116–1120
28. Es Van, Coppens M, Schulman S, Middeldorp S, Buller HR (2014) Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood 124:1968–1975
29. Prins MH, Lensing AW, Bauersachs R, van Bellen B, Bounameaux H et al (2013) Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J 11:21
30. Schulman S, Eriksson H, Goldhaber SZ, Kakkar AJ, Kearon C et al (2013) Influence of active cancer on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RE-COVER II ASH meeting abstract. Blood 122:582
31. Raskob GE, Buller HR, Angchaisuksiri P, Oh D, Boda Z et al (2013) Edoxaban for long-term treatment of venous thromboembolism in cancer patients: a sub-analysis from the Hokusai-VTE trial ASH meeting abstract. Blood 122:211
32. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS et al (2014) Apixaban for the treatment of venous thromboembolism in cancer patients: data from the AMPLIFY trial. Eur Heart J 35:994
33. Kleinjan A, Aggarwal A, van der Geer A, Faselis C, Buller HR et al (2013) A worldwide survey to assess the current approach to the treatment of patients with cancer and venous thromboembolism. Thromb Haemost 110:959–965
34. Lee AY, Kampiusen PW, Meyer G, Bauersachs R, janas MS, jarner MF, Khorana A on behalf of the CATH Investigation (2014) A randomized trial of long-term tinzaparin, a low molecular weight heparin (LMWH), versus warfarin for treatment of acute venous thromboembolism (VTE) in cancer patients—the CATCH Study. Blood 124:LBA 2
35. Monreal M, Falgà C, Valdès M, Suarez C, Gabriel F, Tolosa C, RIETE registry (2006) Fatal pulmonary embolism and fatal bleeding in cancer patients with venous thromboembolism. J Thomb Haemost 4:1950–1956